Phathom Pharmaceuticals, Inc. (PHAT) — SEC Filings
Phathom Pharmaceuticals, Inc. (PHAT) — 46 SEC filings. Latest: 10-Q (Apr 30, 2026). Includes 21 8-K, 7 10-Q, 5 SC 13D/A.
View Phathom Pharmaceuticals, Inc. on SEC EDGAR
Overview
Phathom Pharmaceuticals, Inc. (PHAT) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a DEFA14A filed on Apr 7, 2026: Phathom Pharmaceuticals, Inc. filed a DEFA14A form on April 7, 2026, related to additional definitive proxy soliciting materials. The filing includes various documents such as an iXBRL DEFA14A, graphic files, and XBRL data. The company's mailing and business address is 100 Campus Drive, Suite 102, F
Sentiment Summary
Across 46 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 43 neutral. The dominant filing sentiment for Phathom Pharmaceuticals, Inc. is neutral.
Filing Type Overview
Phathom Pharmaceuticals, Inc. (PHAT) has filed 7 10-Q, 21 8-K, 1 DEFA14A, 1 ARS, 2 DEF 14A, 2 10-K, 3 SC 13G, 5 SC 13D/A, 1 10-K/A, 3 SC 13G/A with the SEC between Jan 2024 to Apr 2026.
Filings by Year
Recent SEC Filings (46)
Risk Profile
Risk Assessment: Of PHAT's 36 recent filings, 2 were flagged as high-risk, 18 as medium-risk, and 16 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Financial Highlights
| Metric | Value |
|---|---|
| Revenue | $117,526,000 |
| Net Income | ($200,100,000) |
| EPS | N/A |
| Debt-to-Equity | N/A |
| Cash Position | $135,156,000 |
| Operating Margin | N/A |
| Total Assets | $240,289,000 |
| Total Debt | $662,823,000 |
Key Executives
- ALBERT CHA
- DANIEL ESTES
- PATRICK J. HERON
- JAMES N. TOPPER
- Albert Cha
- Daniel Estes
- Patrick J. Heron
- James N. Topper
- Terrie Curran
- Yoshihiro Nakagawa
- Shashi Khiani
Industry Context
The pharmaceutical industry is characterized by high R&D costs, lengthy development cycles, and significant regulatory hurdles. Companies often rely on a few key drug approvals for substantial revenue generation. The market is competitive, with established players and emerging biotechs vying for market share. Trends include a focus on specialty drugs, personalized medicine, and increasing scrutiny on drug pricing.
Top Tags
amendment (8) · sec-filing (6) · disclosure (6) · 8-K (6) · financial-reporting (5) · financials (5) · pharmaceuticals (5) · 10-Q (4) · Pharmaceuticals (3) · 8-k (3)
Executive Compensation
From the most recent DEF 14A filing (Apr 12, 2024):
- Terrie Curran — President, Chief Executive Officer and Director
Key Numbers
| Metric | Value | Context |
|---|---|---|
| CIK Number | 0001783183 | Identifies Phathom Pharmaceuticals, Inc. in SEC filings. |
| Filing Date | 2026-04-07 | Date Phathom Pharmaceuticals, Inc. filed the DEFA14A. |
| Product Revenue, Net | $117.5M | Increased from $25.6M in 9M 2024, a 359% rise. |
| Net Loss | ($200.1M) | Improved from ($259.9M) in 9M 2024, but still substantial. |
| Cash and Cash Equivalents | $135.2M | Decreased from $297.3M at Dec 31, 2024, indicating significant cash burn. |
| Total Stockholders' Deficit | ($422.5M) | Widened from ($253.6M) at Dec 31, 2024, reflecting accumulated losses. |
| Net Cash Used in Operating Activities | $161.8M | For the nine months ended Sept 30, 2025, highlighting operational cash drain. |
| Accounts Receivable Concentration | 86% | Three customers accounted for 86% of accounts receivable as of Sept 30, 2025. |
| Product Sales Concentration | 70% | Three customers accounted for 70% of product sales for the nine months ended Sept 30, 2025. |
| Shares Outstanding | 71.1M | As of October 27, 2025, indicating potential dilution. |
| Net Loss (Q2 2025) | $60.3M | Increased from $49.8M in Q2 2024, indicating widening losses. |
| Net Loss (YTD June 2025) | $118.9M | Increased from $98.7M in YTD June 2024, showing accelerated losses. |
| R&D Expenses (Q2 2025) | $15.2M | Decreased from $20.1M in Q2 2024, reflecting a shift in spending. |
| SG&A Expenses (Q2 2025) | $48.2M | Increased from $39.5M in Q2 2024, driven by commercialization efforts. |
| Cash and Cash Equivalents (June 30, 2025) | $150.5M | Decreased from $200.1M at Dec 31, 2024, indicating significant cash burn. |
Forward-Looking Statements
- {"claim":"Invesco Ltd. may have adjusted its holdings in Phathom Pharmaceuticals Inc. due to a re-evaluation of the company's drug pipeline or market position.","entity":"Invesco Ltd.","targetDate":"Q1 2024","confidence":"medium"}
- {"claim":"The stock price of Phathom Pharmaceuticals Inc. could experience short-term volatility as the market reacts to this institutional ownership update.","entity":"Phathom Pharmaceuticals Inc.","targetDate":"February 2024","confidence":"medium"}
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Phathom Pharmaceuticals, Inc. (PHAT)?
Phathom Pharmaceuticals, Inc. has 46 recent SEC filings from Jan 2024 to Apr 2026, including 21 8-K, 7 10-Q, 5 SC 13D/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of PHAT filings?
Across 46 filings, the sentiment breakdown is: 1 bullish, 2 bearish, 43 neutral. The dominant sentiment is neutral.
Where can I find Phathom Pharmaceuticals, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Phathom Pharmaceuticals, Inc. (PHAT) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Phathom Pharmaceuticals, Inc.?
Key financial highlights from Phathom Pharmaceuticals, Inc.'s most recent 10-Q include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for PHAT?
The investment thesis for PHAT includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Phathom Pharmaceuticals, Inc.?
Key executives identified across Phathom Pharmaceuticals, Inc.'s filings include ALBERT CHA, DANIEL ESTES, PATRICK J. HERON, JAMES N. TOPPER, Albert Cha and 6 others.
What are the main risk factors for Phathom Pharmaceuticals, Inc. stock?
Of PHAT's 36 assessed filings, 2 were flagged high-risk, 18 medium-risk, and 16 low-risk.
What are recent predictions and forward guidance from Phathom Pharmaceuticals, Inc.?
Recent forward-looking statements from Phathom Pharmaceuticals, Inc. include guidance on {"claim":"Invesco Ltd. may have adjusted its holdings in Phathom Pharmaceuticals Inc. due to a re-evaluation of the comp and 1 other predictions.